CorMedix Inc. Common Stock CRMD
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-06T22:12:19.165Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T22:02:00.525936524Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-06T22:12:18.604108+00:00
CorMedix Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | 5.02 | 72.4% | 9.1% | |||
| 35Δ | 5.11 | 71.7% | 8.3% | |||
| 40Δ | 5.21 | 71.1% | 7.5% | |||
| 45Δ | 5.84 | 144.1% | 17.4% | 5.31 | 70.4% | 6.7% |
| 50Δ | 5.66 | 133.0% | 14.6% | 5.41 | 69.7% | 5.9% |
| 55Δ | 5.47 | 121.8% | 11.7% | 5.51 | 69.1% | 5.1% |
| 60Δ | 5.29 | 110.6% | 8.8% | 5.61 | 68.4% | 4.3% |
| 65Δ | 5.10 | 99.4% | 6.0% | |||
| 70Δ | ||||||
| 75Δ | ||||||
| 80Δ | 3.86 | 320.7% | 10.5% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.02
- IV
- 72.4%
- B/E move
- 9.1%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.11
- IV
- 71.7%
- B/E move
- 8.3%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.21
- IV
- 71.1%
- B/E move
- 7.5%
45Δ
- Pseudo strike
- 5.84
- IV
- 144.1%
- B/E move
- 17.4%
- Pseudo strike
- 5.31
- IV
- 70.4%
- B/E move
- 6.7%
50Δ
- Pseudo strike
- 5.66
- IV
- 133.0%
- B/E move
- 14.6%
- Pseudo strike
- 5.41
- IV
- 69.7%
- B/E move
- 5.9%
55Δ
- Pseudo strike
- 5.47
- IV
- 121.8%
- B/E move
- 11.7%
- Pseudo strike
- 5.51
- IV
- 69.1%
- B/E move
- 5.1%
60Δ
- Pseudo strike
- 5.29
- IV
- 110.6%
- B/E move
- 8.8%
- Pseudo strike
- 5.61
- IV
- 68.4%
- B/E move
- 4.3%
65Δ
- Pseudo strike
- 5.10
- IV
- 99.4%
- B/E move
- 6.0%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 3.86
- IV
- 320.7%
- B/E move
- 10.5%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 78.21% | |
| 73.72% | |
| 81.15% | |
| 119.67% | |
| 53.76% | |
| 49.64% | |
| 51.91% | |
| 79.72% | |
| 59.69% | |
| 65.23% | |
| 60.91% | |
| 78.83% | |
| 120.67% | |
| 68.73% | |
| 52.75% | |
| 56.08% | |
| 59.65% | |
| 53.90% | |
| 51.49% | |
| 58.77% | |
| 56.69% | |
| 74.87% | |
| 76.02% | |
| 89.77% | |
| 117.20% | |
| 77.36% | |
| 74.51% | |
| 68.67% | |
| 63.14% | |
| 72.15% | |
| 78.07% | |
| 80.06% | |
| 80.38% | |
| 77.26% | |
| 75.50% | |
| 87.02% |
Biotechnology
CRSP
CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. The company is headquartered in Zug,…
More →CRVS
Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. The company is…
More →CTMX
CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. The company is headquartered in South San Francisco, California.
More →CTNM
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation,…
More →CYTK
Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering, developing and commercializing muscle activators and inhibitors as potential…
More →DBVT
Description unavailable
More →